Even if the majority of serum biomarkers (IL-6, IL-8, TNF-α...) currently available have limited specificity for IBD, the dosage of sCP has been proposed as an effective aid both in the management and in predicting long-term outcomes in patients affected by UC and CD [5,26,27,30]. Here, IL6 is linked to irritable bowel syndrome.